Drug intelligence / Profile preview

telmisartan + amlodipine + indapamide

Development stage
Approved
Lead developer
George Medicines
Modality
Small Molecules
Administration
Oral
01

Overview

Telmisartan + amlodipine + indapamide is a fixed-dose, single-pill combination of three antihypertensive agents developed for the treatment of hypertension. The combination includes: - Telmisartan, an angiotensin II receptor blocker (ARB) that inhibits the action of angiotensin II on its receptor, leading to vasodilation and reduced blood pressure. - Amlodipine, a calcium channel blocker (CCB) that relaxes vascular smooth muscle by inhibiting calcium influx into cells. - Indapamide, a thiazide-like diuretic that promotes sodium and water excretion to lower blood volume and pressure. This triple combination is designed to provide rapid and effective blood pressure control with improved tolerability compared to higher doses of individual agents. It has been evaluated in phase III clinical trials for efficacy and safety in adults with hypertension. The product aims to improve patient adherence by simplifying therapy into one pill[1][2][4][6][7].

Brand names
GMRx2GMRx-2GMRx 2
Other names
amlodipine/indapamide/telmisartanindapamide/amlodipine/telmisartantelmisartan/amlodipine/indapamide
02

Targets

AGTR1 (Angiotensin II Type-1 receptor)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)LTCC (Voltage-gated calcium channel (L-type))

Beyond the preview

Go deeper on telmisartan + amlodipine + indapamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on telmisartan + amlodipine + indapamide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call